A man identified as Vincent Mutua was shocked and saddened when he learnt that his son was suffering from kidney cancer, ...
PITTSBURGH — Appendix cancer is a rare cancer that’s often only caught once it has spread. Pittsburgh firefighter Randy Meyer battled it for 10 years. During that time, Randy grew his hair out for a ...
Chronic heartburn, often ignored, can lead to serious oesophageal changes and even cancer, warns gastroenterologist Saurabh ...
Canadians can wait up to two years longer than patients in other G7 countries to get the latest treatments. A recent report ...
The study found that nerves in the digestive system—sometimes called the “second brain”—play a surprising role in helping ...
Ike Onwere, MD: It is [sometimes] based on giving the FOLFOX [leucovorin, fluorouracil, and oxaliplatin] every 2 weeks. It’s ...
The FDA approved perioperative durvalumab (Imfinzi) in combination with a multidrug chemotherapy regimen for resectable ...
James Van Der Beek suited up in his "Varsity Blues" football jersey to help raise money for his cancer treatment.
Imfinzi is the first immunotherapy approved for perioperative use to treat gastric and gastroesophageal junction cancers.
The evidence-based recommendations address how radiation therapy should be used across the spectrum of gastric cancer, from resectable locoregional to metastatic disease.
Novel blood tests as well as artificial intelligence are part of an accelerating effort to catch cancer before it kills.
Findings from the phase 3 MATTERHORN trial supported the FDA approval of perioperative durvalumab for resectable gastric and GEJ cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback